Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 6/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326469 | 0.88 | CNR1 (0.49) | CNR1CNR2SMN1; SMN2FDFT1 | |
| SCHEMBL6332035 | 0.82 | NPC1 (0.47) | CNR1CNR2FDFT1 | |
| SCHEMBL5264037 | 0.81 | CNR1 (0.65) | CNR1CNR2FDFT1 | |
| SCHEMBL6325790 | 0.80 | CNR1 (0.52) | CNR1CNR2TP53MEN1KMT2A | |
| SCHEMBL5262773 | 0.78 | CNR1 (0.72) | CNR1CNR2FDFT1 | |
| SCHEMBL6325667 | 0.77 | CNR1 (0.45) | CNR1CNR2FDFT1 | |
| SCHEMBL6327703 | 0.77 | RAB9A (0.63) | TSHRCNR1CNR2SMN1; SMN2USP2 | |
| SCHEMBL5260117 | 0.77 | CNR1 (0.54) | CNR1CNR2FDFT1 | |
| SCHEMBL5264320 | 0.77 | CNR1 (0.66) | CNR1CNR2FDFT1 | |
| SCHEMBL5262269 | 0.76 | CNR1 (0.63) | CNR1CNR2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | claimed |
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154202-A1 | Substituted aryl amides | CNR1, CNR2, FAAH | TSHR 566/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.